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 14.1 minutes. There was 1 postoperative
death from an unrelated cause, and no tem-
porary or permanent neurologic deficits
were seen. Although this represents a sat-
isfactory outcome, routine adoption of uni-
lateral brain perfusion for TAR, which usu-
ally requires a longer brain protection, may
not always be equally successful. If it has
to be done, however, a more substantial
lowering of core body temperature might
be helpful.
The arch-first strategy described by
Kouchoukos and Masetti1 may not al-
ways be advantageous. This is because it
makes the distal aortic anastomosis more
difficult, with the bulky aortic prosthesis
coming to obscure much of the operative
field. Moreover, deep hypothermia still
needs to be continued during the distal
anastomosis. As Kouchoukos and Ma-
setti1 say, a bilateral anterior thoracot-
omy will facilitate the distal anastomosis
in these situations.
Finally, we think that despite the small
number of patients studied, Kouchoukos
and Masetti1 deserve credit for the results
they obtained with unilateral brain perfu-
sion for TAR. However, preoperative as-
sessment of the cerebral circulation as well
as careful selection of cases should always
be considered before deciding on a brain
protection strategy.
Teruhisa Kazui, MD, PhD
Abul Hasan Muhammad Bashar, MBBS, PhD
Naoki Washiyama, MD, PhD
First Department of Surgery
Hamamatsu University School of Medicine
Hamamatsu, Japan
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Bioengineered airway tissue
To the Editor:
In the brief communication “First Human
Transplantation of a Bioengineered Air-
way Tissue,” Macchiarini and associates1
point out that tracheal replacement by
tissue engineering seems to hold poten-
tial. Question is to be raised whether this
report actually does provide “definitive
evidence that a tissue engineered patch-
. . . can functionally . . . fill all require-
ments for an airway patch.”
The patch was applied to a defect 1.5 
1.5 cm after breakdown of anastomosis af-
ter carinal pneumonectomy. Omentum was
applied over the patch; this was further
buttressed, and the space was filled with a
subscapular muscle flap. To further oblit-
erate the space, complementary thoraco-
plasty was performed. The leak healed, and
ciliated respiratory epithelium was eventu-
ally found to cover the repaired defect.
Closure of a defect such as this with an
omental flap, especially with further use of
a muscle flap plus thoracoplasty to obliter-
ate residual space, would in most cases
suffice to seal the defect successfully. Ep-
ithelium undoubtedly migrates from the re-
spiratory epithelium of the surrounding tra-
chea and bronchus to cover the scar that
forms over the mesenchymally repaired de-
fect. Epithelization occurs over vascular-
ized autogenous flaps used over smaller
defects in trachea and bronchi. Whether the
graft actually survived or the tissue ulti-
mately seen was partly or entirely scar that
would form over the mesenchymal bed of
omentum is not demonstrated.
One must also question placement of a
free graft of any tissue over an area that is
still contaminated, even if not grossly in-
fected, by the bacteria that necessarily are
present in such a situation, despite all
cleanup treatment before repair. More to
the point, however, is the fact that defects
of this sort have long been closed by vas-
cularized pedicled autogenous tissues
(omentum, pericardium, intercostal mus-
cle, and other muscle flaps). Addition of an
engineered tissue graft seems superfluous.
The potential of bioengineering to pro-
duce tracheal replacement segments in the
future is a goal worthy of continued re-
search attention nonetheless.
Hermes C. Grillo, MD
Division of General Thoracic Surgery
Massachusetts General Hospital
Boston, MA 02114
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Reply to the Editor:
It is a distinct privilege to have attracted the
interest of Hermes Grillo, and frankly
speaking, his comments were expected. In
his letter to the Editor, Dr Grillo questions
clinical and experimental issues that I am
delighted to address.
It is certainly correct that the airway
defect could have been closed without the
interposition of the engineered airway tis-
sue. However, we all know that (1) it is
technically demanding and risky to free (by
further devascularizing it) a leaky postra-
diation (70 Gy) carinal anastomosis, and
that (2) an intrathoracic transposed omen-
tum buttressed over an airway defect is
almost never immediately tight, and this
jeopardizes the spillage of omentum pro-
duced fluid into the unique lung and in-
duces a motion- (and foreign body-) tem-
porary cough.
However, and with great respect, we
disagree that the addition of an engineered
airway tissue was superfluous. From a clin-
ical viewpoint, a repeatedly thoracoto-
mized and previously irradiated (70 Gy)
operative field is unlikely to guarantee en-
grafting (eg, intercostals muscle) or allow
harvesting (pericardium) of autogenous tis-
sues. Hence, the closure of the defect with
the tissue-engineered graft ensured a tight
interface permitting a physiologic secretion
transport without having all the complica-
tions related to the indirect closure through
autogenous tissues. Having experienced
the scenario with and without1 this new
tool, I must admit my pleasure in having an
extremely powerful and valid clinical alter-
native.
From an experimental viewpoint, our
disagreement is even more important be-
cause the lessons learned from this clinical
application are very important. Because of
the concise nature of the chosen article
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